Kairos Pharma (KAPA) - Long-Term Debt to Capital

Kairos Pharma Ltd (KAPA) relies on the momentum of scientific research without a current influx of commercial revenue. The company attracts scientists to combat drug resistance by offering them autonomy in R&D. Stability is ensured through the creation of unique molecules in US centers. The ratio of long-term loans to equity visualizes debt safety, and 0.00 shows the current value of the metric.

This ratio measures the proportion of long-term liabilities relative to equity, determining the level of financial leverage and insolvency risk. The current long-term debt-to-equity value is 0.00. For Kairos Pharma Ltd (KAPA), moderate debt is critical when financing the costly cold chain delivery of oncology drugs. Analyzing the trend of this metric allows for an assessment of the balance between infrastructure scaling and maintaining stability. A decrease in the metric confirms a conservative approach to capital, enhancing the asset's investment attractiveness.